All Oncology News

Experts convene during an OncLive Peer Exchange to discuss the evolving treatment paradigm in HR-positive, HER2-negative breast cancer.

Obe-cel was associated with lower rates of CRS and ICANS vs brexu-cel in relapsed or refractory acute lymphoblastic leukemia.

Dana-Farber Cancer Institute’s adult stem cell transplant program and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center’s pediatric stem cell transplant program received exceptional ratings from the CIBMTR.

Bezuclastinib normalized key bone marrow pathology in nonadvanced systemic mastocytosis.

Zev A. Wainberg, MD, discusses different palliative chemotherapy regimens, their use cases, and other recent developments in pancreatic cancer.

Balazs Halmos, MD, MS, and Jamie E. Chaft, MD, discuss how safety considerations contribute to treatment selection in NSCLC.

Neoadjuvant SABR before nephrectomy improved 12-month RFS vs surgery alone in patients with RCC with IVC tumor thrombus, with manageable safety.

The FDA has granted breakthrough therapy designation to JSKN003 in HER2+ platinum-resistant ovarian cancer.

Ceralasertib plus durvalumab did not improve overall survival vs docetaxel in previously treated advanced non–small cell lung cancer.

Tsewang Tashi, MD, discusses long-term avapritinib data in indolent systemic mastocytosis from part 3 of the PIONEER trial.

In the BARCODE1 screening study, prostate cancer testing by polygenic risk score identified a higher percentage than PSA testing or MRI.

Orca-T given with reduced intensity conditioning led to robust myeloid/T-cell engraftment and low rates of acute GVHD in hematologic malignancies.

Interim phase 2 data show nab-sirolimus plus letrozole produced an ORR of 41% and 13.6-month PFS with manageable safety in endometrioid endometrial cancer.

Post-neoadjuvant T-DXd has received breakthrough therapy designation from the FDA for HER2-positive early breast cancer with residual invasive disease.

Pancreatic ductal adenocarcinoma remains highly lethal due to late presentation, treatment resistance, and limited drug delivery with standard systemic therapies.

The FDA has granted accelerated approval to subcutaneous mosunetuzumab for relapsed/refractory follicular lymphoma after 2 prior therapies.

Passion to help individual patients fueled the career of Mark G. Kris, MD, in driving lung cancer research and management.

Experts convened during an OncLive Scientific Interchange and Workshop to discuss evolving considerations for treatment navigation in EGFR-mutant NSCLC.

The NMPA of China has approved pimicotinib, a CSF-1R inhibitor, for the treatment of adults with symptomatic TGCT.

Patients were able to better manage symptoms with digital check-ins and remote care according to researchers at the Mayo Clinic.

The top 5 OncLive TV videos of the week cover insights in myeloma, AML, Ph-positive ALL, pediatric low-grade glioma, and nonadvanced systemic mastocytosis.

Ten-year data from the PORTEC-3 trial show that adjuvant chemoradiotherapy improves OS and RFS vs radiotherapy alone in high-risk endometrial cancer.

The FDA approved T-DXd plus pertuzumab in HER2+ breast cancer, subcutaneous amivantamab in EGFR+ NSCLC, and rucaparib in BRCA-mutated mCRPC.

Only 13% of US patients with CP-CML received FDA-recommended ponatinib dosing, highlighting gaps in dose optimization and the need for education.

Experts reflect on pivotal data, emerging agents, and highly-anticipated trends spanning CML, CLL, B-cell lymphomas, and other hematologic malignancies.

Experts convened during an OncLive Scientific Interchange and Workshop to discuss the evolving treatment landscapes in CSCC and melanoma.

The NMPA has accepted a new drug application for tinengotinib tablets for the treatment of patients with pretreated advanced/metastatic cholangiocarcinoma.

A new study presented at the 2025 ASH Annual Meeting revealed that subtle disruptions in genome architecture can predispose individuals to lymphoma.

Tumor burden and disease status were not correlated with CRS risk or severity in newly diagnosed, relapsed/refractory myeloma managed with elranatamab.

Adam Fox, MD, discusses the need for molecular profiling in non–small cell lung cancer and how these results factor into multidisciplinary planning.